SCHEMBL7226930

SCHEMBL7226930

Fc1ccccc1C1=NNC(=S)Cc2cc3c(cc21)OCO3

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
NPC1 O15118 1/20 0.39
MTOR P42345 1/20 0.39
GRIA2 P42262 3/20 0.37
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
NFKB1 P19838 2/20 0.36
CYP2C19 P33261 2/20 0.36
HIF1A Q16665 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CHRM1 P11229 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234371 0.85 MAPT (0.40) CA1CA2CA4CA6NPC1
SCHEMBL7235789 0.84 GRIA2 (0.47) CA1CA2CA4CA6NPC1
SCHEMBL7236439 0.81 GRIA2 (0.48) GRIA2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7225965 0.77 GRIA2 (0.48) GRIA2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7233697 0.76 GRIA2 (0.41) CA1CA2CA4CA6GRIA2
SCHEMBL7236172 0.72 MEN1 (0.43) CA1CA2CA4CA6NPC1
SCHEMBL7226695 0.72 GRIA2 (0.47) NPC1GRIA2CYP1A2CYP3A4CYP2D6
SCHEMBL6624086 0.68 GRIA2 (0.66) CA1CA2CA4CA6GRIA2
SCHEMBL6625735 0.67 GRIA2 (0.67) GRIA2CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6624904 0.64 GRIA2 (0.67) NPC1GRIA2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888356-B1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AG (DE) 2002-03-20 EP claimed
US-6600036-B2 Treating diseases of the central nervous system. SCHERING AKTIENGESELLSCHAFT (DE) 2003-07-29 US disclosed
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2002-05-02 US disclosed
EP-0888356-B1 CONDENSED 2,3-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS AMPA-RECEPTOR INHIBITORS SCHERING AG (DE) 2002-03-20 EP disclosed
US-6323197-B1 NON-COMPETITIVE INHIBITING OF THE AMPA RECEPTORS, THESE COMPOUNDS CAN BE USED AS MEDICAMENTS FOR TREATMENT OF THE CENTRAL NERVOUS SYSTEM SCHERING AKTIENGESELLSCHAFT (DE) 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052364-A1 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors GABRE, GABRA2, GABRB2 CA1 1220/4885CA2 1341/4885CA4 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.